Skip to main content
SpringerLink
Log in

Antihypertensive Therapie und Fettstoffwechsel

Antihypertensive therapy and lipid metabolism

  • Übersichten
  • Published:
Klinische Wochenschrift Aims and scope Submit manuscript

Summary

Hypertension, hyperlipidaemia and cigarette smoking are major risk factors in coronary heart disease. Since many antihypertensive drugs alter plasma lipid levels it is a subject of current discussion that these agents may increase associated coronary risk and therefore offset the beneficial effects of lowering blood pressure. The purpose of this paper is to review clinical and experimental data in the literature on the influence of antihypertensive drugs on lipid metabolism. The thiazides hydrochlorothiazide and chlorthalidone cause an elevation of plasma triglycerides and very low density lipoprotein (VLDL) but have little effect on total cholesterol, low density lipoprotein (LDL) and high density lipoprotein (HDL). The unspecific beta-blockers, e.g. propranolol, do not affect total cholesterol and LDL but increase total triglycerides and VLDL and decrease HDL. The changes of plasma lipids and lipoproteins caused by cardio-selective beta-blockers, e.g. atenolol and metoprolol, and unspecific beta-blockers with intrinsic sympathomimetic activity (ISA), e.g. oxprenolol and pindolol, appear to be qualitatively similar but less pronounced. The alpha1-blocker prazosin reduces total triglycerides and slightly lowers total cholesterol. The concentration of VLDL plus LDL decreases while HDL may increase. Only very few studies have been reported on the effects of other antihypertensive drugs, e.g. clonidine, hydralazine, on plasma lipids. Several experimental studies reveal that antihypertensive agents exert direct effects on triglyceride and cholesterol metabolism. Although the pathophysiological mechanisms and the significance of the alterations of lipid metabolism induced by antihypertensive drugs are not yet clear, the following guidelines for the clinical use of these agents are recommended: (1) before initiating drug treatment in hypertensive patients, blood lipid levels should be measured to exclude a preexisting hyperlipidaemia, (2) during long-term therapy with antihypertensive agents, lipoprotein fractions should be controlled in order to reconsider the therapeutic regime if major alterations of blood lipid levels are observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

Abbreviations

VLDL:

Very Low Density Lipoprotein

LDL:

Low Density Lipoprotein

HDL:

High Density Lipoprotein

Literatur

  1. Assmann G (1982) Lipidstoffwechsel und Atherosklerose. Schattauer, Stuttgart

    Google Scholar 

  2. Lowenstein J, Nensy A-J (1981) The Biochemical Effects of Antihypertensive Agents and the Impact on Atherosclerosis. J Cardiovasc Pharmacol 3 (Suppl 3):256

    Google Scholar 

  3. Freis ED (1982) Should mild Hypertension be treated? New Engl J Med 307:306

    Article  CAS  PubMed  Google Scholar 

  4. W.H.O./I.S.H. (1982) Mild Hypertension Liaison Committee: Trials of the treatment of mild hypertension. An interim Analysis. Lancet I:149

    Google Scholar 

  5. Multiple Risk Factor Intervention Trial Research Group (1982) Multiple Risk Factor Intervention Trial. JAMA 248:1465

    Article  Google Scholar 

  6. Korcok M (1981) Do antihypertensive drugs increase coronary risk? JAMA 246:2012

    Article  Google Scholar 

  7. Leren P (1982) Bei antihypertensiver Therapie auf Fettstoffwechsel achten. München Med Wschr 3

  8. Havel RJ, Goldstein JL, Brown MS (1980) Lipoprotein and lipid transport. Metabolic control of disease. Bondy PV, Rosenberg LE (Hrsg) 8th edition, WB Saunders, Philadelphia, p 393

    Google Scholar 

  9. Havel RJ (1982) Approach to the patient with hyperlipidemia. Lipid disorders. Havel RJ (Hrsg) The medical clinics of North America 66:319

    Article  CAS  PubMed  Google Scholar 

  10. Nestel PJ, Fidge NH (1981) The physiology of plasma lipoproteins. Lipoproteins, Atherosclerosis and Coronary Heart Disease. Miller NE, Lewis B (Hrsg), Elsevier/North-Holland, Biomedical Press 3

    Google Scholar 

  11. Mahley RW (1982) Atherogenic Hyperlipoproteinemia. Lipid disorders, Havel RJ (Hrsg) The medical clinics of north america 66:375

    Article  CAS  PubMed  Google Scholar 

  12. Zilversmit DB (1979) Atherogenesis: a postprandial phenomenon. Circulation 60:473

    Article  CAS  PubMed  Google Scholar 

  13. Gianturco SH, Gotto AM Jr, Jackson RL et al. (1978) Control of 3-hydroxy-3-methylglutaryl-CoA reductase activity in cultured human fibroblasts by very low density lipoproteins of subjects with hypertriglyceridemia. J Clin Invest 61:320

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Kraemer FB, Chen YDI, Cheung RMC et al. (1981) Binding and degradation of very low density lipoproteins from diabetics by mouse peritoneal macrophages. Circ Res 29:411A

    Google Scholar 

  15. Johnson B, Bye C, Labrooy J (1974) Relation of antihypertensive treatment to plasma lipids and other risk factors in hypertensives. Clin Sci Mol Med 47:9

    Google Scholar 

  16. Gluck Z, Baumgarter G, Wedemann P et al. (1978) Increased ratio between serum β- and α-lipoproteins during diuretic therapy: An adverse effect? Clin Sci Mol Med 55:3255

    Google Scholar 

  17. Grimm RH, Leon AS, Hunninghake RB et al. (1981) Effects of thiazide diuretics on plasma lipids and lipoproteins in mildly hypertensive patients. Ann Intern Med 94:7

    Article  PubMed  Google Scholar 

  18. Johnson BF et al. (1981) The emerging problem of plasma lipid changes during antihypertensive therapy. J Cardiovasc Pharmacol 3 (Suppl 3):172

    Google Scholar 

  19. Ames RP, Hill P (1978) Raised serum lipid concentrations during diuretic treatment of hypertension: a study of predictive indeces. Clin Sci Mol Med 55:311

    Google Scholar 

  20. Johnson BF, Munro-Faure AD, Slack J (1976) Diuretic-induced hypertriglyceridemia. Lancet I:1019

    Article  Google Scholar 

  21. Herbert PN (1983) Effect of propranolol on blood lipids and lipoproteins in myocardial infarction. Presented at Symposium on beta-blockers and lipid metabolism. Heidelberg, FRG

  22. Joos C, Kewitz H, Reinhold-Kourniati D (1980) Effects of diuretics on plasma lipoproteins in healthy men. Eur J Clin Pharmacol 17:251

    Article  CAS  PubMed  Google Scholar 

  23. Ames RP, Hill P (1976) Elevation of serum lipids levels during therapy of hypertension. Amer J Med 61:748

    Article  CAS  PubMed  Google Scholar 

  24. Helgeland A, Hjermann I, Holme U, Loen P (1978) Serum triglycerides and serum uric acid in untreated and thiazide-treated patients with mild hypertension. Amer J Med 64:34

    Article  CAS  PubMed  Google Scholar 

  25. Helgeland A, Hjermann I, Loen P, Holme I (1978) Possible metabolic side effects of beta adrenergic blocking drugs. Brit Med J 1:828

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. von Brummelen P, Gevers-Lauren JA, van Gent CM (1979) Influence of hydrochlorothiazide on the plasma levels of triglycerides, total cholesterol and HDL-cholesterol in patients with essential hypertension. Curr Med Res Opin 6:24

    Article  PubMed  Google Scholar 

  27. Ames RP, Hill P (1981) Antihypertensive therapy and the risk of coronary heart disease. J Cardiovasc Pharmacol 3 (Suppl 3):160

    Google Scholar 

  28. Holzgreve, Schwandt P (1983) Effects of long-term hypertensive therapy with beta blockers and diuretics on serum lipoproteins. Presented at symposium on beta blockers and lipid metabolism, Heidelberg, FRG

  29. Meier A, Schiffl H, Weidemann P, Mordasini R, Riesen W, Bachmann C (1981) β-receptor-blocking agents may reverse or prevent diuretic induced increases in serum low-density lipoprotein cholesterol. Clin Sci 61:437

    Article  Google Scholar 

  30. Ames RP, Hill P (1976) Raised serum-lipids during treatment of hypertension with Chlorthalidone. Lancet I:721

    Article  Google Scholar 

  31. Gluck Z, Weidmann P, Mordasini R. et al. (1980) Increased serum low-density lipoprotein cholesterol in men treated short term with the diuretic chlorthalidone. Metabolism 29:240

    Article  CAS  PubMed  Google Scholar 

  32. Gluck Z et al. (1978) Increased ratio between serum β- and α-lipoproteins during diuretic therapy: an adverse effect? Clin Sci Mol Med 55:325

    Google Scholar 

  33. Schnaper H, Fitz A, Frohlich E et al. (1977) Chlorthalidone and serum cholesterol. Lancet II:295

    Article  Google Scholar 

  34. Gluck Z, Weidmann P, Mordasini R et al. (1979) Einfluß einer Diuretikatherapie auf die Serumlipoproteine: Ein unerwünschter Effekt? Schweiz Med Wschr 109:104

    CAS  PubMed  Google Scholar 

  35. Goldmann AI, Steele BW, Schnaper HW et al. (1980) Serum lipoprotein levels during chlorthalidone therapy. JAMA 244:1691

    Article  Google Scholar 

  36. Falck DK, Schreiner A (1983) The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration. Acta Med Scand 213:27

    Article  Google Scholar 

  37. Leren P et al. (1982) Antihypertensive drugs and blood lipids. The Oslo study. Brit J Clin Pharmacol 13 (Suppl 2):441

    Article  Google Scholar 

  38. Day JL, Simpson N, Metcalfe J, Page RL (1979) Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Brit Med J 1:77

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Bielmann P, Leduc G, Davignon J (1980) Beta-blockers and changes in lipoprotein fractions. New Engl J Med 302:298

    CAS  PubMed  Google Scholar 

  40. Leren P et al. (1981) Antihypertensive drugs and blood lipids: The Oslo study. J Cardiovasc Pharmacol 3 (Suppl 3):187

    Google Scholar 

  41. Gemma G, Montanari G, Suppa G et al. (1981) Plasma lipid and lipoprotein changes in hypertensive patients treated with propranolol and prazosin. J Cardiovasc Pharmacol 3 (Suppl 3):207

    Google Scholar 

  42. Shaw J, England JDF, Hua ASP (1978) Beta-blockers and plasma triglycerides. Brit Med J 1:986

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Moorjani et al. (1980) VII. Int Symp Dr aff Lip Met 546

  44. Berglung et al. (1976) Acta med Scand 199:499

    Article  Google Scholar 

  45. Leren P, Foss PO, Helgeland A et al. (1980) Effect of propranolol and prazosin on blood lipids. The Oslo study. Lancet II:4

    Article  Google Scholar 

  46. Loyd-Mostyn RH, Lefevre D, Lord PS et al. (1971) The effect of beta-adrenergic blocking agents on serum lipids. Atherosclerosis 14:283

    Article  Google Scholar 

  47. Streja D, Mymin D (1978) Effect of propranolol on HDL-cholesterol concentrations. Brit Med J 2:1495

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Miettinen TA et al. (1980) Atherosclerosis 36:249

    Article  CAS  PubMed  Google Scholar 

  49. Berglund G et al. (1981) Lancet I:744

    Article  Google Scholar 

  50. Tanaka N et al. (1976) Effect of chronic administration of propranolol on lipoprotein composition. Metabolism 25:1071

    Article  CAS  PubMed  Google Scholar 

  51. Bauer JH, Brooks CS, Weinstein I et al. (1981) Effects of diuretics and propranolol on plasma lipoprotein's lipids. Clin Pharmacol Ther 30:35

    Article  CAS  PubMed  Google Scholar 

  52. Schauer I, Schauer U, Ruhling K et al. (1980) The effect of propranolol treatment on total cholesterol, HDL cholesterol, triglycerides, postheparin lipolytic activity and lecithin: cholesterol acyltransferase in hypertensive individuals. Artery 8:146

    CAS  PubMed  Google Scholar 

  53. England JDF (1981) Aust NZJ Med 11:36

    Article  Google Scholar 

  54. Lehtonen A, Hietanen E, Marnieni J et al. (1982) Effect of pindolol on serum lipids and lipid metabolizing enzymes. Brit J Clin Pharmacol 13 (Suppl 2):445

    Article  Google Scholar 

  55. Leren P, Foss OP, Helgeland A et al. (1981) Effects of pindolol and hydrochlorothiazide on blood lipids. The Oslo study. Clin Trials 18:254

    Google Scholar 

  56. Pasotti Ch, Capra A, Fiorella G et al. (1982) Effects of pindolol and metoprolol on plasma lipids and lipoproteins. Brit J Clin Pharmacol 13 (Suppl 2):435

    Article  Google Scholar 

  57. Miettinen TA, Vanhauen H, Huttunen JK et al. (1982) HDL cholesterol andβ-adrenoceptor blocking agents in a 5-year multifactorial primary prevention trial. Brit J Clin Pharmacol 13 (Suppl 2):431

    Article  Google Scholar 

  58. Ballantyne D, Ballantyne FC, McMurdo (1981) Effect of slow oxprenolol and a combination of slow oxprenolol and cyclopenthiazide on plasma lipoproteins. Atherosclerosis 39:301

    Article  CAS  PubMed  Google Scholar 

  59. Kjeldsen SE, Eide I, Loen P et al. (1982) The effect on HDL cholesterol of oxprenolol and atenolol. Scand J Clin Lab Invest 42:449

    Article  CAS  PubMed  Google Scholar 

  60. Crisp AJ, Kennedy PGE, Hoffbrand BI et al (1980) Lipids and lipoprotein fraction after cyclopenthiazide and oxprenolol: a double-blind crossover study. Curr Med Res Opin 7:101

    Article  CAS  PubMed  Google Scholar 

  61. England JDF, Senions LA, Gibson JC et al. (1980) The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clin Exp Pharmacol Physiol 7:329

    Article  CAS  PubMed  Google Scholar 

  62. Eliasson K, Lins L-E, Rössner S (1981) Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 20:335

    Article  CAS  PubMed  Google Scholar 

  63. Rössner S, Weiner B (1983) Hypertension therapy: Comparison between 50 mg atenolol and 200 mg propranolol daily. (in press)

  64. Waal-Manning HJ (1980) The effect of beta-blockers on plasma lipids. Presented at Symposium on Beta-Blocker Therapy, Atlanta, Georgia

  65. Weiner L, Rössner S (1982) A comparison between 50 mg atenolol and 200 mg metoprolol/day with regard to blood pressure, side effects and serum lipoproteins. Int Soc Hypertension Mexico 440A

  66. Waal-Manning HJ, Simpson FO (1977) Beta blockers and lipid metabolism. Brit Med J 1:705

    Article  Google Scholar 

  67. Tuomilekto J, Nissinen A (1980) Experiences with metoprolol durules, a slow-release formulation in hypertension. J int Med Res 8:44

    Google Scholar 

  68. Waal-Manning HJ (1976) Metabolic effects ofβ-adrenoceptor blockers. Drugs 11:121

    Article  PubMed  Google Scholar 

  69. Beinart IW, Cramp DG, Pearson RM et al. (1979) The effect of metoprolol on plasma lipids. Postgrad med J 55:709

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  70. Nilsson A et al. (1978) Europ J Clin Pharm 13:5

    Article  CAS  PubMed  Google Scholar 

  71. Nilsson A, Hansson BG, Hökfelt B (1977) Betablockers and lipid metabolism. Brit Med J 2:126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Moorjani et al. (1980) VII. Int Symp Dr aff Lip Met, 546

  73. Sirtory (1981) In: Kaplan N: Summary. J Cardiovasc Pharmacol 3 (Suppl 3):261

    Google Scholar 

  74. Velasco M, Silva H, Morillo J et al. (1981) Effect of prazosin on blood lipids and on thyroid function in hypertensive patients. J Cardiovas Pharmacol 3 (Suppl 3):193

    Google Scholar 

  75. Havard CWH, Khokhar AM, Flax JS (1981) Open assessment of the effect of prazosin on plasma lipids. J Cardiovasc Pharmacol 3 (Suppl 3):216

    Google Scholar 

  76. Montanari G, Suppa G, Paralovo A et al. (1981) Plasma lipid and lipoprotein changes in hypertensive patients treated with propranolol and prazosin. Int Soc Hypertension, Italy (abstr)

  77. Kokubu T, Itoh I, Kurita H et al. (1981) Effect of prazosin on serum lipids. J Cardiovasc Pharmacol 3 (Suppl 3):199

    Google Scholar 

  78. Lithell H, Waern U, Vessby B (1981) Effect of prazosin on lipoprotein metabolism in premenopausal hypertensive women. J Cardiovasc Pharmacol 3 (Suppl 3):223

    Google Scholar 

  79. Kirkendall WM, Hammond JJ, Thomas JC et al. (1978) Prazosin and Clonidine for moderately severe hypertension. JAMA 240:2553

    Article  CAS  PubMed  Google Scholar 

  80. Perry HM Jr, Mills EJ (1962) The effect of oral hydralazine on circulating human cholesterol. Amer J Med Sci 243:564

    Article  CAS  PubMed  Google Scholar 

  81. Ghiselli G, Bernini F, Nursanti R et al. (1981) Effect of L-Propranolol on the binding, internalization and degradation of 125I-low density lipoproteins by human skin fibroblasts. Biochem Biophys Res Comm 103:1060

    Article  CAS  PubMed  Google Scholar 

  82. Stout RW et al. (1983) Dibutyryl cyclicAMP inhibits LDL binding in cultured fibroblasts and arterial smooth muscle cells. Atherosclerosis 46:13

    Article  CAS  PubMed  Google Scholar 

  83. Efendić S, Östman J (1970) Catecholamines and metabolism of human adipose tissue. Acta med Scand 187:493

    Article  PubMed  Google Scholar 

  84. Ellis S (1980) Effects on the metabolism. Adrenergic Activators and Inhibitors part I (Szekeres EL Hrsg) Handbook of Exp Pharmacol, Vol 54, I, Springer, New York, p 334

    Google Scholar 

  85. Lafontain M, Berlan M (1980) Evidence for theα-2 nature of theα-adrenergic receptor inhibitor in lipolysis in human fat cells. Eur J Pharmacol 66:87

    Article  Google Scholar 

  86. Kather H, Simon B (1981) Adrenoceptor of the alpha2-subtype mediating inhibition of the human fat cell adenylate cyclase. Eur J Clin Invest 11:111

    Article  CAS  PubMed  Google Scholar 

  87. Wright EE, Simpson ER (1981) Inhibition of the lipolytic action ofβ-adrenergic agonists in human adipocytes byα-adrenergic agonists. J Lipid Res 22:1265

    CAS  PubMed  Google Scholar 

  88. Burns TW, Laugley PE, Terry BE, Bylung DB, Forte LR (1982) Alpha-adrenergic activation inhibits foskolin-stimulated adenylate cyclase activity and lipolysis in human adipocytes. Life Sci 31:815

    Article  CAS  PubMed  Google Scholar 

  89. Kawamura M, Jensen DF, Wancewicz EV, Joy LL, Khoo JC, Steinberg D (1981) Hormone-sensitive lipase in differentiated 3T3-L1 cells and its activation by cyclic AMP-dependent protein-kinase. Proc Nat Acad Sci USA 78:732

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Krone W, Müller-Wieland D, Wilke A, Greten H (1982) Effects ofα- andβ-adrenergic receptor stimulation on sterol synthesis in human lymphocytes. Ateriosclerosis 2:413A

Download references

Author information

Authors and Affiliations

  1. Medizinische Kernklinik und Poliklinik Universitäts-Krankenhaus Eppendorf, Hamburg

    W. Krone, D. Müller-Wieland & H. Greten

Authors
  1. W. Krone
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. D. Müller-Wieland
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Greten
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Krone, W., Müller-Wieland, D. & Greten, H. Antihypertensive Therapie und Fettstoffwechsel. Klin Wochenschr 62, 193–202 (1984). https://doi.org/10.1007/BF01721044

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01721044

Key words

Search

Navigation